Drug Safety Oversight Board Proceedings Should Be More Open, Rep. DeLauro Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA Commissioner Crawford defends the board as an "instrument of openness" in response to complaints that the panel's closed proceedings will fail to provide greater transparency.
You may also be interested in...
FDA Drug Safety Board Will Impact All "Medical Product" Activities, Crawford Says
Commissioner plans to appeal to the House appropriations subcommittee for additional funding of agency programs.
FDA Drug Safety Board Will Impact All "Medical Product" Activities, Crawford Says
Commissioner plans to appeal to the House appropriations subcommittee for additional funding of agency programs.